Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 1-10

  Lu, Li ^a,b,c   Kanwar, Jyoti ^b,c   Schmitt, Sara ^b,c   Cui, Qiuzhi Cindy ^b,c   Zhang, Chuanyin ^a   Zhao, Cong ^a   Dou, Q Ping ^b,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer therapy; Medicinal compounds; Proteasome inhibitors; Triptolide

Indexed keywords

PROTEASOME; TRIPTOLIDE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CHINESE MEDICINE; COLONY FORMATION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DITERPENES; EPOXY COMPOUNDS; FEMALE; HUMANS; I-KAPPA B PROTEINS; MALE; PHENANTHRENES; PLANTS, MEDICINAL; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 79851474637     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tao X, Younger J, Fan FZ, Wang B and Lipsky PE: Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 46: 1735-1743, 2002. (Pubitemid 34774504)
2. Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 42: 253-265, 2001.
3. Matta R, Wang XX, Ge H, Ray W, Nelin LD and Liu Y: Triptolide induces anti-inflammatory cellular responses. Am J Transi Res 1: 267-282, 2009.
4. Pan JX: RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett 292: 149-52, 2010.
5. Mujumdar N, MacKenzie T, Dudeja V, Chugh R, Antonoff MB, Borja-Cacho D, Sangwan V, Dawra R, Vickers SM, Saluja AK: Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 139: 598-608, 2010.
6. Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444, 2009.
7. Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 2: 215-223, 1999. (Pubitemid 29526245)
8. Goldberg AL: Functions of the proteasome: the lysis at the end of the tunnel. Science 268: 522-523, 1995.
9. Chen ZJ, Parent L and Maniatis T: Site-specific phosphorylation of IκBa by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853-862, 1996. (Pubitemid 26106855)
10. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002. (Pubitemid 34449723)
11. Yang HJ, Zhou P, Huang HB, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, Wang X, Dou QP and Liu J: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459, 2009.
12. Smith DM, Daniel KG and Dou QP: Exploiting the ubiquitin-proteasome pathway for anticancer drug discovery: unanswered questions and future directions. Lett Drug Des Discov 2: 77-84, 2005.
13. Adam J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421, 2004.
14. An B, Goldfarb RH, Siman R and Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062-1075, 1998.
15. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR and Dou QP: Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69: 1421-1432, 2005. (Pubitemid 40602442)
16. Kazi A, Urbizu DA, Kuhn DJ, Acebo AL, Jackson ER, Greenfelder GP, Kumar NB and Dou QP: A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed cells. Int J Mol Med 6: 879-887, 2003.
17. Yang HJ, Chen D, Cui QC, Xiao Y and Dou QP: Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4764, 2006.
18. Yang HJ, Shi GQ and Dou QP: The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from 'Indian winter cherry'. Mol Pharmacol 71: 426-437, 2007.
19. Milacic V, Banerjee S, Landis KR, Sarkar FH, Majumdar AP and Dou QP: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68: 7283-7292, 2008.
20. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P and Yan G: A small molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of NF-kappa B pathway. Mol Pharmacol 75: 812-819, 2009.
21. Qiu DM, Zhao GH, Aoki YS, Shi L, Uyei A, Nazarian S, Ng JC and Kao PN: Immunosuppressant PG490 (Triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kB transcriptional activation. J Biol Chem 274: 13443-13450, 1999
22. Yan X, Bi CF, Fan YH, Cui C, Zhang X and Dou QP: L-glutamine schiff base copper complex as a proteasome inhibitor and an apoptosis inducer in human cancer cells. Int J Oncol 33: 1073-1079, 2008.
23. Chen Di, Frezza M, Shakya R, Cui QC, Milacic V, Verani CN and Dou QP: Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti-prostate tumor effects. Cancer Res 67: 9258-9265, 2007. (Pubitemid 47535914)
24. Nam S, Smith DM and Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276: 13322-13330, 2001.
25. Kupchan SM, Court WA, Dailey RG Jr., Gilmore CJ and Bryan RF: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94: 7194-7195, 1972.
26. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC and Andreeff M: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111: 3742-3750, 2008.
27. Dou KR, Farrell AT, Sridhara R and Pazdur R: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12: 2955-2960, 2006. (Pubitemid 43837337)
28. Gong Y, Xue B, Jiao J, Jing L and Wang X: Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 107: 779-788, 2008.
29. Kang DW, Lee JY, Oh DH, Park SY, Woo TM, Kim MK, Park MH, Jang YH and Min do S: Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exper Mol Med 41: 678-685, 2009.
30. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F: Resveratrol: from basic science to the clinic. Cell Cycle 6: 2495-2510, 2007. (Pubitemid 350058668)
31. Kiviharju TM, Lecane PS, Sellers RG and Peehl DM: Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 8: 2666-2674, 2002. (Pubitemid 34856355)